Brand Name

Levobunolol

View Brand Information
FDA approval date: March 04, 1994
Classification: beta-Adrenergic Blocker
Form: Solution

What is Levobunolol?

Levobunolol hydrochloride ophthalmic solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker.
Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker.
Journal: Pharmacology research & perspectives
Published: October 20, 2025
Drugs for open-angle glaucoma.
Drugs for open-angle glaucoma.
Journal: The Medical letter on drugs and therapeutics
Published: April 22, 2025
A national analysis of systemic adverse events of beta-blockers used for glaucoma therapy.
A national analysis of systemic adverse events of beta-blockers used for glaucoma therapy.
Journal: Cutaneous and ocular toxicology
Published: September 12, 2024
View All Latest Advances